Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateBicara TherapeuticsCompass Therapeutics
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Tiziana doses last patient in Phase 2 Alzheimer's trial of intranasal foralumabOct 16Clinical readoutforalumabTiziana Life Sciences LTD
Spyre Therapeutics files preliminary prospectus for common stock offeringOct 5FinancingSpyre Therapeutics, Inc.
Sign in